Drug intelligence / Profile preview

Kezimuke Keli

Development stage: Unknown
Lead developer: Xinjiang Altay Region Kazakh Medical Hospital
Modality: Small Molecules
Administration: Oral

Overview

Kezimuke Keli is a traditional Kazakh medicine (TKM) developed by the Xinjiang Altay Region Kazakh Medical Hospital. Formulated as oral granules, it is specifically indicated for the treatment of acute uncomplicated lower urinary tract infections. In the framework of Kazakh medical theory, the preparation is used to clear heat, eliminate toxins, and promote diuresis to alleviate symptoms such as urgency, frequency, and painful urination (dysuria). The drug has undergone clinical evaluation in China, including Phase III trials, to establish its efficacy and safety profile as a botanical-based therapy for urological conditions.

Brand names: Kezimuke Keli
Other names: Kezimuke Granules克孜木克颗粒

Beyond the preview

Go deeper on Kezimuke Keli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kezimuke Keli.

Explore the full profile